00000nam 2200000zi 4500 9.934797 CaOODSP 20240410112705 m o d f cr mn||||||||| 240301e20240308onc ob f000 0 eng d 9780660705675 (report) 9780660705682 (summary) CaOODSP eng rda CaOODSP n-cn--- HP40-352/1-2024E-PDF HP40-352/2-2024E-PDF Updated guidance on the use of protein subunit COVID-19 vaccine (Novavax Nuvaxovid). Ottawa, ON : Public Health Agency of Canada = Agence de la santé publique du Canada, March 8, 2024. ©2024 1 online resource (12 pages, 3 unnumbered pages) + 1 summary (4 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Cover title. Issued also in French under title: Mise à jour des directives sur l'utilisation du vaccin à sous-unités protéiques contre la COVID-19 (Nuvaxovid de Novavax). At head of title: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Pub.: 230829 (report). Pub.: 230831 (summary). Includes bibliographical references. COVID-19 vaccines Canada. Public Health Agency of Canada, issuing body. Canada. National Advisory Committee on Immunization, issuing body. Mise à jour des directives sur l'utilisation du vaccin à sous-unités protéiques contre la COVID-19 (Nuvaxovid de Novavax). (CaOODSP)9.934798 PDF 638 KB https://publications.gc.ca/collections/collection_2024/aspc-phac/HP40-352-1-2024-eng.pdf Report PDF 485 KB https://publications.gc.ca/collections/collection_2024/aspc-phac/HP40-352-2-2024-eng.pdf Summary HTML N/A https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-updated-guidance-use-protein-subunit-covid-19-vaccine-novavax-nuvaxovid.html Report HTML N/A https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-updated-guidance-use-protein-subunit-covid-19-vaccine-novavax-nuvaxovid.html Summary